A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
Status:
Withdrawn
Trial end date:
2024-06-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective
compared to vedolizumab and placebo in participants with moderately to severely active
ulcerative colitis (UC).